| Svc Of Elmhurst Llc | |
|
8635 Queens Blvd, Elmhurst, NY 11373-4434 | |
| (631) 727-2858 | |
| Not Available |
| Full Name | Svc Of Elmhurst Llc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 8635 Queens Blvd, Elmhurst, New York |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134739493 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| 332H00000X | Eyewear Supplier | (* (Not Available)) | Secondary |
| Provider Name | Jeffrey Slaney Williams |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1225024490 PECOS PAC ID: 6901813310 Enrollment ID: I20060309000442 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Jeffrey Slaney Williams |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1396945143 PECOS PAC ID: 3870687593 Enrollment ID: I20071108000578 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Cynthia Wiener |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1063896926 PECOS PAC ID: 5890088306 Enrollment ID: I20160721000489 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Preeti K Minhas |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1447744263 PECOS PAC ID: 9739437575 Enrollment ID: I20180809005581 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Jin Yip Chiu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1104469287 PECOS PAC ID: 5092149179 Enrollment ID: I20191224000176 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Michelle Anne Mckillop |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1851917256 PECOS PAC ID: 4880012137 Enrollment ID: I20200917002798 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Ava Louise Koch |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1275143075 PECOS PAC ID: 8628488152 Enrollment ID: I20201111002181 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Gina Nicole Dericco |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1588287312 PECOS PAC ID: 3577974658 Enrollment ID: I20201120001128 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Zhongyue Hu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1841814043 PECOS PAC ID: 7719399849 Enrollment ID: I20201215001596 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Alicia Jones |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1437776960 PECOS PAC ID: 1759796907 Enrollment ID: I20210219002351 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Raazia Syedda |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1386217974 PECOS PAC ID: 3779987391 Enrollment ID: I20210804001999 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Mohit Batra |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1386211563 PECOS PAC ID: 9234533894 Enrollment ID: I20210804003473 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Gurkiran Kaur |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1144957366 PECOS PAC ID: 6305221904 Enrollment ID: I20220919000746 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Paige M Thomas |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1861166035 PECOS PAC ID: 2264817725 Enrollment ID: I20220920000213 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Provider Name | Bryan Sookoo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1467010173 PECOS PAC ID: 0345651121 Enrollment ID: I20221123001113 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Svc Of Elmhurst Llc 1224 Ostrander Avenue, Riverhead, NY 11901 Ph: (631) 727-2858 | Svc Of Elmhurst Llc 8635 Queens Blvd, Elmhurst, NY 11373-4434 Ph: (631) 727-2858 |
News Archive
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.
Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 7 days ago
Family Optical Ny, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 8327 Broadway Ste 1f, Elmhurst, NY 11373 Phone: 917-651-6870 | |
Dr. Charles Kim, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 94-07a 46 Avenue, 2nd Floor, Elmhurst, NY 11373 Phone: 917-385-7829 | |
Mount Sinai Elmhurst Faculty Practice Group Optometrist Medicare: Not Enrolled in Medicare Practice Location: 7901 Broadway, Elmhurst, NY 11373 Phone: 718-334-1591 Fax: 718-334-4815 | |
Eric C. Rubinfeld, Optometrist Medicare: Medicare Enrolled Practice Location: 9015 Queens Blvd, Queens Center Mall, Elmhurst, NY 11373 Phone: 718-592-5200 Fax: 718-592-7902 | |
Rebecca Revital Khalili, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 9141 Queens Blvd, Elmhurst, NY 11373 Phone: 210-524-6922 | |
Dr. Stephen Luloff, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 86-15 Queens Blvd, Elmhurst, NY 11373 Phone: 718-899-6600 Fax: 718-397-7782 | |
Cohen's Fashion Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 9015 Queens Blvd, Elmhurst, NY 11373 Phone: 718-592-5200 Fax: 718-592-7902 |